All News
ACR Best Abstracts - Day 4
The final day (day 4) of the ACR 2020 meeting saw a flurry of late-breaking abstracts and other novel studies that excited our faculty. Below are some of their choices for #ACRbest.
Read Article
Rheumatology Round-Up 2020 Tonight!
Rheumatology Round-Up tonight 8:00pm EST, 7pm CST. Drs. Artie Kavanaugh and Jack Cush reprise their long-running end of ACR highlights. Rheums can watch by Zoom (Q&A too), everyone can watch on RheumNow.com or our YouTube channel. See you there!
Read Article
“Rheumatologists diagnose diseases of inflammation, and we are really good at it!” - Dr. Greg Silverman #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
About half (51%) of patients from the FORWARD registry in the US had at least one telehealth appointment during COVID-19 pandemic and most were satisfied with the appointment @RheumNow #ACR20 Abstr#1962 https://t.co/z38ilD1n8Q
Dr. Antoni Chan synovialjoints ( View Tweet)
Summary of #ACR20 part A:
- HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation
- Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS
@rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by @RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Hey Google, does this patient have sacroilitis?
Artificial intelligence model validated for detection of radiographic sacroilitis.
@RheumNow #ACR20 Abs#2018 https://t.co/TDhGKC8ss4
Robert B Chao, MD doctorRBC ( View Tweet)
What was the effect of COVID-19 in axSpA patients? From @rheum_cat In the early phase of COVID-19 there was a higher levels of stress and anxiety leading to higher BASDAI scores @RheumNow #ACR20 Abstr#1884
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow
Eric Dein ejdein1 ( View Tweet)
Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
Eric Dein ejdein1 ( View Tweet)
The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890
Dr. Antoni Chan synovialjoints ( View Tweet)
Test your ACR IQ and see where you place on our leaderboard. #ACR20
https://t.co/DKSq8gKTDb https://t.co/lGUEbVbg1g
Links:
Dr. John Cush RheumNow ( View Tweet)
2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD. @RheumNow #ACRBest https://t.co/7b7chCPRxm
Eric Dein ejdein1 ( View Tweet)
COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs.
⬇️radiographic spinal progression over 2 yrs
⬇️mSASSS progression
@RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma
Robert B Chao, MD doctorRBC ( View Tweet)
Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor
-HZ events more common in patients taking 30mg vs 15mg
-HZ more common in UPA vs those taking ADA+MTX & MTX
Abs#2002 #ACR20 @RheumNow
https://t.co/tQ03wBueW5
Mrinalini Dey DrMiniDey ( View Tweet)
We as young physicians should start paying attention to our contracts-🤦♀️
1-know your worth (see MGMA compensation yearly)
2-malpractive/ tail coverage
3-non-compete
4-termination clause
5-guarantee/ RVU
@RheumNow
#ACR20 #5M036
Bella Mehta bella_mehta ( View Tweet)
Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
Enormous potential, worth exploring!
Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Round-Up tonight 8pm EST, 7pm CST. Artie Kavanaugh and Jack Cush reprise their long running end of ACR highlights. Rheums can watch by zoom (Q&A too), everyone can watch on https://t.co/V10S4oVFsv or our YouTube channel. See you there! https://t.co/74OIAiMTx3
Links:
Dr. John Cush RheumNow ( View Tweet)
Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment.
Abs#2000 #ACR20 @RheumNow
https://t.co/lt8xDT4Ne8
Mrinalini Dey DrMiniDey ( View Tweet)